Cerebral open flow microperfusion (cOFM)-HILIC-HRMS platform for in vivo and in situ monitoring of tumor microenvironment in glioblastoma.

in Analytica chimica acta by Fernanda Monedeiro, Denise Schimek, Eva-Maria Prugger, Thomas Altendorfer-Kroath, Elmar Zügner, Christoph Magnes

TLDR

  • A novel research platform combining cOFM and HILIC-HRMS-based metabolomics was developed to characterize the local metabolic phenotype of human glioblastoma in a xenograft animal model.
  • The platform detected a significant number of discriminant metabolites in ISF samples, potentially enabling personalized medicine applications for glioblastoma treatment.

Abstract

Glioblastoma exhibits a very poor prognosis and profound metabolic alterations associated to its aggressiveness. Examining tumor metabolic states is crucial for identifying potential therapeutic targets, enabling personalized medicine applications. However, direct access to the functional glioblastoma tumor microenvironment (TME) in vivo is highly challenging, particularly due to the tumor location and risk of blood-brain-barrier disruption. Here, we developed a novel research platform combining the innovative sampling technology cerebral open flow microperfusion (cOFM) and HILIC-HRMS-based metabolomics to comprehensively characterize the local metabolic phenotype of human glioblastoma in xenograft animal model. Interstitial fluid (ISF) collected directly from the functional inner TME without trauma generation using cOFM, plasma (PL) and cerebrospinal fluid (CSF) were analyzed. The proposed method enabled consistent measurements, detecting nearly 400 metabolites with adequate analytical quality in the study samples, of which 281 were found in brain ISF. ISF presented the highest number of discriminant metabolites, with over 30 % of the metabolome found to be altered in tumors compared to controls (p < 0.05). Fewer significant metabolic changes were assessed in CSF. Correlation analysis of ISF and PL indicated distinct metabolic fluxes through lipid metabolism in these two compartments. Pathway enrichment analysis indicated significant alterations in pathways related to mechanisms contributing to glioblastoma progression. Evaluation of ISF samples revealed that glioblastoma metabolic reprogramming may involve altered activity of ABC transporters, fatty acid oxidation, enhanced metabolism of central carbon, arginine, proline, and amino acid derivatives engaged in redox homeostasis. Evaluation of PL samples indicated a pronounced contribution of systemic lipid-mediated signaling. ISF presented metabolic features and pathway activities from functional unaffected tumor, portraying metabolic traits of human glioblastoma tissue and corroborating the translational potential of this method. The novel cOFM-HILIC-HRMS research platform for in vivo/in situ monitoring of TME in glioblastoma can offer a promising and standardized tool for neuro-oncological research in the field of drug resistance and therapy development.

Overview

  • The study explores the development of a novel research platform to characterize the local metabolic phenotype of human glioblastoma in a xenograft animal model.
  • The platform combines cerebral open flow microperfusion (cOFM) and HILIC-HRMS-based metabolomics to analyze interstitial fluid (ISF), plasma (PL), and cerebrospinal fluid (CSF) samples.
  • The aim is to identify potential therapeutic targets and enable personalized medicine applications for glioblastoma treatment.

Comparative Analysis & Findings

  • ISF samples detected nearly 400 metabolites, with 281 found in brain ISF, and showed a significant number of discriminant metabolites, with over 30% altered in tumors compared to controls (p < 0.05).
  • Fewer significant metabolic changes were observed in CSF samples compared to ISF.
  • Pathway enrichment analysis indicated significant alterations in pathways related to mechanisms contributing to glioblastoma progression, such as altered activity of ABC transporters, fatty acid oxidation, and enhanced metabolism of central carbon, arginine, proline, and amino acid derivatives.

Implications and Future Directions

  • The novel research platform has the potential to become a standardized tool for neuro-oncological research in the field of drug resistance and therapy development.
  • Future studies can build on this research to explore the translational potential of the method for human glioblastoma and identify novel therapeutic targets.
  • The platform can also be applied to other diseases and conditions affecting the brain to gain insights into their metabolic phenotypes and potential therapeutic strategies.
Read Full Article